Nabriva Therapeutics to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference
May 08 2019 - 4:01PM
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical
company engaged in the development of innovative anti-infective
agents to treat serious infections, today announced that Ted
Schroeder, Chief Executive Officer, will provide a company overview
and business update at the Bank of America Merrill Lynch 2019
Healthcare Conference in Las Vegas on Wednesday, May 15, 2019 at
4:20 p.m. PT.
The presentation will be webcast live and may be
accessed by visiting the "Investors" section of the Company's
website under the "Events and Presentations" tab at
www.nabriva.com. A replay of the webcast will be available for 90
days.
About Nabriva Therapeutics
plcNabriva Therapeutics is a biopharmaceutical company
engaged in the development of innovative anti-infective agents to
treat serious infections. Nabriva Therapeutics has two product
candidates that are in late stage development: lefamulin,
potentially the first systemic pleuromutilin antibiotic for
community-acquired bacterial pneumonia (CABP) and CONTEPO
(fosfomycin) for injection, a potential first-in-class epoxide
antibiotic in the United States for complicated urinary tract
infections (cUTIs) including acute pyelonephritis (AP). For more
information, please visit https://www.nabriva.com.
Forward-Looking StatementsAny
statements in this press release about future expectations, plans
and prospects for Nabriva Therapeutics, including but not limited
to statements about Nabriva Therapeutics’ plans for further
interactions with the FDA and EMA; the development of Nabriva
Therapeutics’ product candidates, such as the future development or
commercialization of lefamulin and CONTEPO, the clinical utility of
lefamulin for CABP and of CONTEPO for cUTI, plans for and timing of
the review of regulatory filings, efforts to bring lefamulin and
CONTEPO to market, plans to enter into arrangements with third
parties to commercialize lefamulin in Europe, if approved; the
market opportunity for and the potential market acceptance of
lefamulin for CABP and CONTEPO for cUTI, the potential benefits
under its license agreements with Sinovant Sciences, Ltd. and
Sunovion Pharmaceutics Canada, Inc., the development of lefamulin
and CONTEPO for additional indications, the development of
additional formulations of lefamulin and CONTEPO, plans to pursue
research and development of other product candidates, its ability
to achieve any of the specified regulatory or performance
milestones under its loan agreement with Hercules Capital, the
sufficiency of Nabriva Therapeutics’ existing cash resources and
other statements containing the words “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “predict,”
“project,” “target,” “potential,” “likely,” “will,” “would,”
“could,” “should,” “continue,” and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: Nabriva
Therapeutics’ ability to resolve the matters set forth in the
Complete Response Letter it received from the FDA in connection
with its NDA for CONTEPO (fosfomycin) for injection; Nabriva
Therapeutics’ reliance on third-party manufacturers to manufacture
the clinical and commercial supply of its product candidates and
the ability of such third parties to comply with applicable
regulatory requirements; the content and timing of decisions made
by the U.S. Food and Drug Administration and other regulatory
authorities, Nabriva Therapeutics’ ability to realize the
anticipated benefits, synergies and growth prospects of its
acquisition of Zavante Therapeutics, the uncertainties inherent in
the initiation and conduct of clinical trials, availability and
timing of data from clinical trials, whether results of early
clinical trials or studies in different disease indications will be
indicative of the results of ongoing or future trials, whether
results of ZEUS will be indicative of results for any ongoing or
future clinical trials and studies of CONTEPO, uncertainties
associated with regulatory review of clinical trials and
applications for marketing approvals, the availability or
commercial potential of product candidates including lefamulin for
use as a first-line empiric monotherapy for the treatment of CABP
and CONTEPO for the treatment of cUTI, the ability to retain and
hire key personnel, the sufficiency of cash resources and need for
additional financing and such other important factors as are set
forth in Nabriva Therapeutics’ annual and quarterly reports and
other filings on file with the U.S. Securities and Exchange
Commission. In addition, the forward-looking statements included in
this press release represent Nabriva Therapeutics’ views as of the
date of this press release. Nabriva Therapeutics anticipates that
subsequent events and developments will cause its views to change.
However, while Nabriva Therapeutics may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Nabriva Therapeutics’ views as of any date subsequent
to the date of this press release.
CONTACTS:
FOR INVESTORS
Dave GarrettNabriva Therapeutics
plcdavid.garrett@nabriva.com 610-816-6657
FOR MEDIAMike BeyerSam Brown Inc.
mikebeyer@sambrown.com312-961-2502
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Sep 2023 to Sep 2024